Teva Pharmaceutical Industries Limited
HealthcareNYSE:TEVA · New York Stock Exchange
+$0.07 today
Vol 4.51M · Avg 6.41M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $3.7B |
| Receivables | $3.4B |
| Inventory | $3.2B |
| Other Current | $3.4B |
| Total Current Assets | $13.7B |
| PP&E (Net) | $4.3B |
| Goodwill | $15.8B |
| Intangible Assets | $3.6B |
| Tax Assets | $2.2B |
| Other Non-current | $376.0M |
| Total Non-current Assets | $26.3B |
| Total Assets | $40.0B |
Analysis
Selected assets total $40.0B for Latest. The largest visible component is Goodwill at $15.8B, about 39.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.6B +7.8% | $3.3B +2.3% | $3.2B +15.2% | $2.8B +29.4% | $2.2B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $3.7B +21.2% | $3.1B -10.2% | $3.4B -7.8% | $3.7B -18.4% | $4.5B | $533.8M | $399.4M | -$1.7B |
| Inventory | $3.2B +5.7% | $3.0B -25.2% | $4.0B +4.9% | $3.8B +0.4% | $3.8B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $2.4B +9.2% | $2.2B +279.1% | $575.0M +2.9% | $559.0M -43.3% | $986.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $13.9B +11.1% | $12.6B +0.5% | $12.5B +3.6% | $12.1B -4.2% | $12.6B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $4.4B -10.6% | $4.9B -19.5% | $6.1B -0.2% | $6.2B -4.9% | $6.5B | $1.2B | $1.5B | $687.8M |
| Goodwill | $16.0B +5.6% | $15.1B -11.8% | $17.2B -2.6% | $17.6B -12.0% | $20.0B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $3.8B -14.4% | $4.4B -18.0% | $5.4B -14.1% | $6.3B -16.0% | $7.5B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 -100.0% | $8.0M | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $2.2B +21.8% | $1.8B -0.7% | $1.8B +24.3% | $1.5B +144.6% | $596.0M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $405.0M -12.3% | $462.0M +0.0% | $462.0M +4.8% | $441.0M -14.4% | $515.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $26.8B +0.1% | $26.8B -13.6% | $31.0B -3.0% | $32.0B -8.9% | $35.1B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $40.7B +3.6% | $39.3B -9.6% | $43.5B -1.2% | $44.0B -7.7% | $47.7B | $13.3B | $11.9B | $10.6B |
| Account Payables | $2.5B +14.9% | $2.2B -15.3% | $2.6B +37.9% | $1.9B +11.9% | $1.7B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $1.8B +2.2% | $1.8B +6.5% | $1.7B -20.7% | $2.1B +47.9% | $1.4B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $8.4B +39.0% | $6.0B +15.7% | $5.2B -2.3% | $5.3B -6.7% | $5.7B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $13.5B +5.2% | $12.8B +4.5% | $12.2B +6.8% | $11.5B +4.0% | $11.0B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $15.3B -4.6% | $16.0B -11.9% | $18.2B -4.9% | $19.1B -11.6% | $21.6B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $296.0M -38.7% | $483.0M -20.3% | $606.0M +10.6% | $548.0M -30.1% | $784.0M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $3.5B -12.6% | $4.0B +0.2% | $4.0B +1.9% | $3.9B +53.0% | $2.6B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $19.4B -6.9% | $20.8B -9.9% | $23.1B -3.5% | $23.9B -5.7% | $25.4B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $32.8B -2.3% | $33.6B -4.9% | $35.4B -0.2% | $35.4B -2.8% | $36.4B | $14.7B | $3.7B | $9.6B |
| Common Stock | $58.0M +0.0% | $58.0M +1.8% | $57.0M +0.0% | $57.0M +0.0% | $57.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$13.8B +9.3% | -$15.2B -12.1% | -$13.5B -4.3% | -$13.0B -23.2% | -$10.5B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$2.4B +24.0% | -$3.1B -16.7% | -$2.7B +5.0% | -$2.8B -5.8% | -$2.7B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 -100.0% | $1.0M | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $4.0M -98.8% | $347.0M -44.0% | $620.0M -21.9% | $794.0M -17.8% | $966.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $7.9B +38.4% | $5.7B -29.6% | $8.1B -5.5% | $8.6B -23.5% | $11.2B | $9.1B | $7.7B | $3.3B |
| Total Debt | $17.4B -3.9% | $18.1B -10.3% | $20.2B -6.5% | $21.6B -8.1% | $23.5B | $724.2M | $410.6M | $399.4M |
| Net Debt | $13.8B -6.4% | $14.8B -12.7% | $16.9B -9.8% | $18.8B -11.9% | $21.3B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Natera, Inc.
NASDAQ:NTRA
$30.37B
Biogen Inc.
NASDAQ:BIIB
$29.53B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
Waters Corporation
NYSE:WAT
$23.17B
BioNTech SE
NASDAQ:BNTX
$22.90B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
STERIS plc
NYSE:STE
$20.26B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Insulet Corporation
NASDAQ:PODD
$10.37B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does TEVA have?
Teva Pharmaceutical Industries Limited (TEVA) reported $3.56B in cash and equivalents in fiscal 2025.
How much debt does TEVA carry?
Teva Pharmaceutical Industries Limited (TEVA) reported $17.38B of total debt, with net debt of $13.83B.
Explore More
Continue the stock analysis
Jump to another research area for this company.